Share Name Share Symbol Market Type Share ISIN Share Description
Genetix Grp LSE:GTX London Ordinary Share GB0001276863
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 84.00p 0.00p 0.00p - - - 0 06:32:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 26.2 2.1 2.7 30.8 60.95

Genetix Grp Share Discussion Threads

Showing 151 to 174 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
Hold recommendation from Growth Company Investor
Bit worried here that although they are leaders at the moment, what happens if someone invents a new tech? Although i suppose the same could be said for many a share. Also, wouldnt want to buy in after such a spike caused purely by the tipsheet. Interesting share though. If it goes back into the 40s then i might look again.
Price shot up by over 25% after being tipped by RHPS on April 3rd !
Had another brief mention as a possible positive candidate in Trendwatch recently. Also mentioned here today-
Trading statement out today. Confirms GTX are in line with expectations. "Charles de Rohan, Chief Executive of Genetix, commented: "We made further good progress in 2008 despite the wider economic conditions and volatile exchange rate markets. Our strategy of investing in the business to drive top line growth and underlying profitability and earnings per share is bearing fruit and positions us well to deliver sustained shareholder value. "The Group is profitable, financially strong and benefits from a number of defensive qualities. We continue to tightly manage our cost base in line with the current economic trading environment. With world class products and deep customer relationships, the business is well placed and able to meet the opportunities and challenges for the coming year" Market cap = £39.13m Cash = £15.2m EV = £24m In line with market expectations for FY 2008 confirmed, which are: EPS = 6p PBT = £4.76m They will gain further benefit from the weak GBPUSD exchange rate over the coming year & have the possibility of using that large cash pile to make earning enhancing acquisitions. Stripping out the cash puts GTX on a PE of less than 6 for FY2008, which for a company with a large cash pile, growing earnings in a traditionally defensive sector looks good value. I continue to hold.
I bought some GTX today. No debt, half market cap covered by cash, positive cash flow, sales growth of 20% per year. 44% of earnings in dollars last year so the exchange rate will provide a nice boost going forward. New CEO joined earlier this year bringing a greater sales focus. EPS forecast of 6p for 08, stripping out cash that puts them on a PE of just over 3. With the potential of using the cash pile for acquisitions to boost growth these look attractively priced.
Gets a brief mention in Trendwatch from the other day commenting on its good growth record.
Genetix Group plc -- AGM Statement -- New Milton, UK, 7 May 2008 - Genetix Group plc (AIM:GTX) ("Genetix" or the " Company"), the cancer diagnostic and biopharmaceutical technologies group, will hold its Annual General Meeting (AGM) today at 11.30 a.m. During the course of the meeting Mark Reid, Chief Executive of Genetix, will make the following statement to shareholders: "Genetix has made a positive start to the year and is trading in line with our expectations. Investing in the sales infrastructure and serving our principal markets well continues to be a priority. As part of this process we have recently established a direct sales presence in Japan to more effectively channel our sales efforts in this important territory. We remain excited about the opportunities within our chosen markets and are making good progress with the Company's research and development pipeline with the aim of enhancing our product range and delivering the competitive edge we provide to our customers. The Board remains confident of the outlook for the full year and looks forward to continuing to update the market with our progress."
y cymro
TUESDAY MARCH 4 In-line numbers are expected from Genetix Group PLC, the cell identification and selection group. Sales for the year ended Dec 31 2007 (which includes a full twelve months of results for Applied Imaging) are expected to show a 48 pct increase to 22.9 mln stg. The key growth driver during the year was the company's cell biology product family which showed excellent sales growth of 44 pct to 6.5 mln stg. Owing to the strength of sterling versus the dollar throughout 2007, on a constant currency basis, sales in the year would have been around 23.8 mln, an increase of 54 pct. In the first full year of ownership Applied Imaging achieved revenues of 9.9 mln stg and an operating profit of 1.5 mln, and the integration of this business is now complete
Featured on the growth company investor website today. It's the first time I've looked at these since 2000/2001. It's good to see survivors from that era starting to make it at last.
Genetix Group plc Trading update for the year ended 31 December 2007 New Milton, UK, 17 January 2008 - Genetix Group plc (AIM:GTX), the cell identification and selection group, today provides an update on trading ahead of its preliminary results for the year ended 31 December 2007, which are expected to be announced at the beginning of March 2008. Sales for the year ended 31 December 2007 (which includes a full twelve months of results for Applied Imaging) are expected to be £22.9 million (2006: £15.5 million), being an increase of 48% on the previous year. The key growth driver during the year was our cell biology product family which showed excellent sales growth of 44% to £6.5 million. Owing to the strength of sterling versus the dollar throughout 2007, on a constant currency basis sales in the year would have been approximately £23.8 million, being an increase of 54%. In our first full year of ownership Applied Imaging achieved revenues of £9.9 million and an operating profit of £1.5 million and the integration of this business is now complete. Since acquiring Applied Imaging in November 2006 we have transformed it from a loss making business into one which is a significant source of profitability for the Group as a whole and we are encouraged by the future growth prospects of this operation. Gross margin in the year has improved by over 3% to 60% reflecting an improved product mix with the key driver being the excellent sales growth in our cell biology products. We have continued to invest in the business including developing our sales and marketing infrastructure as well as R&D, the latter of which will enable us to launch two new products in Q1 2008, the Cell Reporter and the Chromoscan 120 Slide Loader, which we believe have excellent prospects. Pre-tax profits before amortisation of acquired intangibles, to 31 December 2007 are expected to be in-line with market expectations and the Board remains confident about the Group's prospects for 2008. Mark Reid, Chief Executive, commented: "2007 was a year of substantial progress for Genetix as we capitalised on the growing market for our cell biology products and completed the integration of Applied Imaging. We are making a number of strategic investments in the sales infrastructure and are launching two exciting new products that will drive further momentum in sales growth in our chosen markets and are optimistic for the year ahead."
Fantastic trading statement this morning but does not look like many are following... Any comments?
Article from FT - April 4th. Long but well worth a read. ---- Mark Reid has a homely way to describe what his company does: "Think of companies that make the kit to produce beer. We are doing a similar job to them." But the "beer" referred to by the chief executive of Genetix is a concoction of proteins and other genetic fragments that offer the potential to form new molecules useful to pharmaceutical companies. Genetix, based in New Milton, Hampshire, is one of a few companies in the world making the complicated machines that help in development and production of new pharmaceutical products based on biotechnology. Biotech companies use Genetix equipment to analyse samples and assess whether their properties make them suitable drugs. Genetix also makes small quantities of the substances for testing or as a prelude to full-scale production. For a manufacturing company with a strong technology bias, it may seem surprising that Genetix's 51- year-old founder is a former accountant, who taught himself chemistry in the 1980s after developing an urge to join the sector. Indeed, nearly all other businesses in this field were founded by scientists rather than accountants, but Mr Reid does not see this as a handicap: "I have taught myself what I need to know, and can leave all the really technical matters to other people," he says. His lack of scientific background appears to have done him no harm: his 59 per cent stake in Genetix is now worth £33m. After an initial foray into the basic industry of plastics moulding, Mr Reid founded Genetix in 1991. This is still a fledgling industry and steering a way through the many changes in the sector has required both dogged perseverence and an ability to change tack when required. The business of biotech instrumentation – and the chemicals used with the machines – enjoys total global sales of about $2bn (£1bn) a year. Genetix's competitors in this field are mainly from the US, and include big makers of scientific instruments such as Thermo Fisher, Bio-Rad Laboratories and PerkinElmer as well as more specialised biotech groups such as Applied Biosystems and Affymetrix. The development of such equipment was triggered by rapid advances in the past 20 or so years in gene-based techniques for fighting disease. "We are in the dawn of a new era of medicine in which a range of new treatments based on proteins and similar materials is becoming possible," says Mr Reid. But keeping abreast of industry trends – not to mention coping with the vagaries of government funding, particularly in the US – has not been easy. A number of Mr Reid's smaller competitors have either gone under or been swallowed up by bigger groups, making him a rare UK-based survivor in the sector. The US-based Genomic Solutions and the UK's Biorobotics, two small businesses making similar products to Genetix, have both in recent years passed into the hands of big companies, and are now both owned by Harvard Bioscience. In the late 1990s, government cash was pouring into the race to decode the human genome, prompting the industry to focus on the search for the structure of DNA. But now there is more emphasis on cell biology and practical ways to "harvest" proteins and similar materials that could be useful in therapy and diagnosis. So while Genetix started out by producing machines geared mainly to uncovering the structure of DNA samples, the company has since changed tack. Its latest families of machines – which sell for up to £200,000 – include equipment that analyses samples of cells, to check on their propensity to manufacture certain types of proteins that could become useful medicines, while also monitoring the rate at which they create such molecules. "We are getting some encouraging feedback from customers [in the pharmaceutical industry] that the machines are doing a useful job," says Mr Reid. Another positive sign for the company is that roughly half the expected sales in 2007 of about £27m are likely to come from products and specialist software introduced over the past year with particular contributions from the new "cell sample" machines plus software. Of special relevance to this last point is Genetix's £13.6m purchase last year of Applied Imaging, a ­California-based company specialising in the imaging software that is increasingly required in biotech-based instruments. Underlining the importance of the US to the biotech field, some 60 per cent of the company's revenues in 2007 is likely to come from North America, which is where it has 50 of its 165-strong staff, with most of the rest located in the New Milton headquarters just outside Bournemouth. Research and development is important to Genetix: some 40 per cent of its staff work in this field (including software) and only 20 in manufacturing – all of whom work at the New Milton site. The company's share price reflects the shifts in the industry. After floating in 2000 at a share price of £1.50 this quickly rose to £2.50 only to slump to 25p in 2003 on the back of a fall in fortunes in the entire biotech sector, which was linked partly to a run of poor results from some leading biotech companies. After a better run of profits, however, Genetix's share price has rebounded to 80p. Last year, in recording pre-tax profits of £3.2m on sales of £15.5m, the company registered a pre-tax profit margin of 20 per cent. Having lasted the distance so far, Mr Reid names Renishaw as the company he would most like Genetix to emulate. This highly successful medium-sized UK-based business in measuring instruments, with annual sales of £173m, was set up in 1973 by Sir David McMurtry, who remains in charge as chairman and chief executive. "If I could create something like Renishaw, it would be fantastic," says Mr Reid. A timely injection of learning After starting out as an accountant with KPMG, Mark Reid decided there could be more to working life than spreadsheets and company audits. He decided to try manufacturing and in 1985 bought Plastic Injection, a Dorset-based moulding business that is now part of Jarden, a US company. "But I soon found out that making injection moulded plastic parts wasn't an easy business," Mr Reid says. "I had to do something different from all the competitors, or face severe problems." He achieved that partly thanks to a friend who was a chemistry lecturer at Southampton University. By sitting at the back of the friend's lecture room – without enrolling on a course – the ex-accountant absorbed some useful know-how about polymer chemistry. He learned enough to work out how to position Plastic Injection into an "upmarket" area of the plastics business in which it worked with novel and tough but mouldable plastics to form components used, for instance, in oil and gas pipelines. Another breakthrough came after some chance contacts in the late 1980s with scientists at the Imperial Cancer Research Fund in London, who asked Mr Reid to produce plastic components for a new family of genetic machines they wanted to develop as part of the effort to sequence the human genome. "We worked out how to make the parts and they (the scientists) were happy," Mr Reid says. "Then they asked us if we could make the whole machine .̴1;. . I thought we could have a go." He found a group of engineers who could do the technical work and started the biotechnology instrumentation company Genetix in 1991. Its first premises were the spare bedroom of David Norton, a former colleague who was a co-founder Genetix but left soon after to leave Mr Reid running it on its own. Genetix's first product, called the Qbot, worked out the significance of tiny samples of genetic fragments and was useful in analysing DNA samples. Based on the ICRF's designs, it sold for £60,000.
Anybody still holding these? New product release from Genetix, sounds pretty good. This is exactly the type of product, with value added from new acquisition AIS, that will mean GTX will grow their sales more than the forecast this year. AGM is on May 9th, hopefully an update on trading then.
Looks like the sellers are working overtime. Time to stack up more!
For long term holders it's nice to see some movement after the long period of stagnation following the fall from grace.
Good to see the price on the up with some decent volumes. The web site shows a press release for a new product and also a new newsletter, see; This stick is ready to hit 85p before its next interim report. Recommended as a 'strong buy' and will continue to rise... =================== Wednesday, 17th January 2007 07:54 Genetix Group sees FY profits ahead of forecast, improved gross margins LONDON (AFX) - Cell biology company Genetix Group PLC said it expects its full year profits to be ahead of expectations due to improved gross margins and US dollar exchange gains, with sales excluding new acquisition Applied Imaging Corp in line with market expectations. The company said it expects Applied Imaging, which the company bought for 25.8 mln usd cash in November, to make a 'meaningful contribution' to the company's profitability over the period. =================== Wednesday, 22nd November 2006 09:06 Genetix completes acquisition of US-based Applied Imaging for 25.8 mln usd LONDON (AFX) - AIM-listed cell biology company Genetix Group PLC said it has completed the acquisition of US-based Applied Imaging Corp for about 25.8 mln usd cash. Genetix said the acquisition will increase its strength in cell imaging and analysis, allowing it to exploit 'growth opportunities' in both the drug discovery and clinical diagnostics markets. The company first announced an 18.3 mln usd cash bid for Applied Imaging on Sept 1 and since then had been forced to hike the offer several times by an unnamed rival bidder. =================== Wednesday, 22nd November 2006 08:18 UK smallcap opening - Genetix better as Applied Imaging deal completed LONDON (AFX) - Buyers came for Genetix Group, 7 pence better at 59-1/2, as the cell biology and health technology group completed the acquisition of Applied Imaging for around 25.8 mln usd cash (about 13.6 mln stg).
Is there a break fee if GTX decide too much?
see above! dpd - 23 Mar'05 - 11:50 - 20 of 25 dont wast your money
with the new products coming on line i recomend Genetix as a buy. A lot of intrest from the pharma side of there market.
Genetix "buy," target price raised LONDON, March 1 ( - Analyst Jonathan Kwok of Panmure Gordon & (LSE: PMR.L - news) amp; Co maintains his "buy" rating on Genetix Group (LSE: GTX.L - news) (ticker: GTX (NASDAQ: GTXI - news) -GBX). The target price has been raised from 61p to 68p. In a research note published this morning, the analyst mentions that the company has reported its top-line and bottom-line for 2005 ahead of the estimates, primarily due to substantial gross margin expansion, mix shift to high-margin products and an increase in instrumentation sales. Genetix has posted a sequential decline in its R&D and sales & marketing costs and a sequential increase in its interest income for the year. Anyone any thoughts on this one - cash must pretty much underpin the price at this level.
Decent enough results. However, only 55% of profit before tax is from operations - the remainder is interest received on the £25m cash pile their holding. This company exhibits similar characteristics to Celsis (CEL) which also holds a significant amount of cash. Celsis does pays a (smallish) dividend whereas no mention of dividends in the Genetix statement today. The Celsis share price has traded within a narrow range for 18 months now. The biotech sector doesn't appear popular with investors at present and hasn't been for 2 or 3 years.
I'm around having bought at 227 back in the dark ages All I seem to hear is the future is rosy, I sure hope so. What say ya'll
ace beekeeper
Chat Pages: 7  6  5  4  3  2  1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180119 05:57:57